세계 경구용 단백질 및 펩타이드 시장은 2025-2032년 예측 기간 동안 13.66%의 CAGR로 2024년 66억 7,000만 달러에서 2032년 185억 8,000만 달러로 성장할 것으로 예상됩니다. 경구용 단백질과 펩타이드는 주사 대신 정제나 캡슐 형태로 입으로 섭취하는 치료용 생체분자입니다.
경구용 펩타이드와 단백질은 더 나은 의료 전달 기술과 접근성 높은 치료 솔루션에 대한 환자들의 관심이 높아지면서 전 세계적으로 큰 폭의 시장 성장을 보이고 있습니다. 경구용 단백질 및 펩타이드 치료는 주사제보다 간편하기 때문에 만성질환을 관리하는 환자들에게 선호되고 있습니다. 암 및 위장 장애와 더불어 당뇨병 치료에서도 경구용 펩타이드 제제는 더 나은 치료 결과와 향상된 약물 흡수율로 인해 큰 이점을 가져다 줍니다.
혁신적인 캡슐화 기술과 침투 촉진제 개발로 오랜 기간 지속된 영양 흡수 어려움과 효소 분해 문제를 해결하는 데 성공했습니다. 주요 제약사들은 연구개발에 막대한 자금을 투입하여 제품 라인을 확대하는 한편, 바이오테크놀러지 기업과의 전략적 제휴를 통해 시장 진입을 가속화하고 있습니다.
북미와 유럽의 의료 시스템은 강력한 인프라와 의료 연구에 많은 투자를 하는 능력으로 시장을 선도하고 있습니다. 아시아태평양의 의료 분야는 의료에 대한 인식이 높아지고 투자 활동이 활발해짐에 따라 유망한 성장 전망을 보이고 있습니다.
만성질환은 지속적으로 증가하고 있으며, 의료 산업은 맞춤형 의료 제공 시스템으로 전환하고 있기 때문에 규제의 복잡성과 제조상의 어려움에도 불구하고 시장 성장은 지속될 것으로 보입니다. 예를 들어, 2023년 Eli Lilly and Company는 Dice Therapeutics를 24억 달러에 인수하여 경구용 펩타이드 치료, 특히 자가면역질환을 치료하는 IL-17 억제제에 대한 깊은 관심을 보이고 있습니다. 업계는 환자들이 주사제보다 편리하다고 느끼는 새로운 치료 옵션에 대한 움직임을 보이고 있습니다.
Global oral proteins and peptides market is projected to witness a CAGR of 13.66% during the forecast period 2025-2032, growing from USD 6.67 billion in 2024 to USD 18.58 billion in 2032. Oral proteins and peptides are therapeutic biomolecules taken through the mouth in the form of tablets and capsules instead of injections.
Oral peptides and proteins are experiencing substantial market growth worldwide because of better medical delivery techniques combined with growing patient interest in accessible therapeutic solutions. Oral protein and peptide treatment has become the preferred option for patients who manage chronic conditions because of its simplicity over injectable medications. The treatment of diabetes alongside cancer and gastrointestinal disorders benefits greatly from oral peptide formulations because they provide better therapeutic outcomes and improved drug absorption.
The development of innovative encapsulation technologies and penetration enhancers has successfully resolved nutritional absorption difficulties and enzymatic degradation problems that lasted for a long time. Leading pharmaceutical companies dedicate substantial funding to research and development to grow their product lines while establishing strategic alliances with biotechnology organizations to speed up market entry.
The healthcare systems of North America and Europe lead the market because of their strong infrastructure and their ability to invest heavily in medical research. The healthcare domain of the Asia-Pacific region shows promising growth prospects because of increased healthcare awareness combined with growing investment activities in the region.
Market growth will continue despite regulatory complexity and manufacturing challenges since chronic diseases keep increasing, and the healthcare industry is moving toward personalized medicine delivery systems. For instance, in 2023, Eli Lilly and Company purchased Dice Therapeutics for USD 2.4 billion to demonstrate their deep interest in oral peptide therapy, especially for IL-17 inhibitors, which treat autoimmune conditions. The industry demonstrates a movement toward new treatment options, which patients find more convenient than injectable drugs.
Rising Prevalence of Chronic Disease Boosts Market Demand
The rising prevalence of chronic disease is increasing due to diabetes, cardiovascular disorders, obesity, and gastrointestinal conditions, which will boost the need for oral proteins and peptides as a more user-friendly treatment alternative to injections. The healthcare system faces a growing disease burden because of modern sedentary living habits, which are paired with unhealthy eating patterns and rising stress levels while dealing with an aging population. For instance, according to the International Diabetes Federation, about 539 million adults are currently dealing with diabetes, and the number is expected to increase to 853 million by the year 2050. The growing diabetes epidemic supports the increased market sales of oral peptide therapeutics such as GLP-1 agonists.
Furthermore, cancer and autoimmune diseases are also less common, and advanced biologic treatments are needed as the second line of treatment. With compliance factors encountered with injectable biologics, traditional injectable alternatives are an attractive option for continuous, long-term treatment. Health providers and governments are putting patients first, which is driving R&D to deliver oral protein more quickly. These trends quickly require innovative, non-invasive therapies to prevent chronic disease and boost market demand effectively.
Advancement in Drug Discovery Technology to Uplift Market Expansion
Expected growth in the oral proteins and peptides market will be fueled by modern advancements in drug discovery techniques. New technologies such as AI-enabled drug design, high-throughput screening, and computational modeling support the identification of peptides closer to any notion of stability and bioavailability. New delivery systems such as nanoparticle carriers and permeation enhancers allow peptides to overcome traditional challenges, including poor absorption and enzymatic degradation after oral administration. Formulation technologies such as enteric coatings and protease inhibitors improve oral bioavailability as well. In addition, biotech companies are also tapping into unique CRISPR and mRNA platforms to develop next-generation peptide therapeutics.
Additionally, key players are focusing on advanced technology for the development of oral proteins and peptides. For instance, in June 2024, Biora Therapeutics, Inc. announced the results of preclinical trials of its latest technology, the BioJet Systemic Oral Delivery Platform, at the Next Gen Peptide Formulation & Delivery conference. This technology is used as an ingestible device designed to transit through the digestive system and activate in the small intestine. Such advanced technology increased the potential of oral protein and peptides therapies in targeted delivery, by providing alternatives to injections and expanding the uses of various medical treatments.
Tablets Hold the Largest Market Share of the Oral Protein and Peptides Market
The oral protein and peptides market is dominated by tablets due to limitations of the oral form of protein and peptides, so they are most common. Tablets' unique solid dosage form allows a lot more convenience in administration, provides longer shelf stability than liquids or powders, with precise dosage, and if needed, doesn't need to be refrigerated. Innovations (technologies) in formulating biomolecules (enteric and controlled release formulation technologies) have impacted biologically sensitive biomolecules and their capability to produce sensitive biomolecules and novel forms of sensitive biologic oral delivery. Tablets are also less expensive to manufacture and ship than a vial or liquid drug, which makes them the most developed and accepted delivery form for pharmaceutical companies, because there are accepted manufacturing, distribution, and marketing pathways for tablets. While there are some alternative formats also available today (i.e., capsules, oral films), tablets or solid dosage forms are the historically most trusted and accepted dosage form for chronic treatments (demand for protein and peptide delivery by the oral route).
For instance, in April 2025, Merck & Co., Inc. announced that peptide drugs may soon be available in convenient oral tablet form through a USD 493 million licensing deal with Austria-based drug delivery technology maker Cyprumed.
North America Dominates the Oral Proteins and Peptides Market
North America is dominant in the global oral proteins and peptides market due to its cutting-edge healthcare infrastructure, strong research and development capabilities, and high demand for advanced biological therapies. The established pharmaceutical sector, along with flexible regulations in this region, allows quick development and market entry of novel oral protein-based medical solutions. The increasing occurrence of chronic diseases, especially diabetes and gastrointestinal disorders, creates a growing market for convenient oral peptide treatment options. North America strengthens its market leadership through major biotechnology investments and the rising popularity of non-invasive drug delivery methods. The region remains dominant in the emerging oral proteins and peptides industry through continuous drug formulation technology combined with expanding clinical applications.
Additionally, most of the pharmaceutical companies' headquarters are in North America. Along with the key industry players, numerous medical research organizations are propelling market growth by launching new products or innovative research. For instance, in February 2024, Johnson & Johnson Services, Inc., presented phase 2b FRONTIER 1 trial results for JNJ-2113, the first oral peptides under development for the treatment of moderate to severe plaque psoriasis (PsO).
Impact of U.S. Tariffs on Oral Proteins and Peptides Market
The global protein and peptide market shows significant disruptions due to the U.S. tariff implementation because it affects supply networks and generates cost spikes for manufacturers and end consumers. Organizations today need to select between absorbing their higher expenses and shifting these costs to their customers because current elevated tariffs apply to finished goods and raw materials, resulting in lower market effectiveness. The economic effects of U.S. import changes have generated difficulties for developing countries that rely heavily on American products, so these nations have begun to change their trading approaches and discover fresh supply chain options. The implementation of new tariffs has both encouraged local production development and produced financial challenges for small enterprises to handle their debts. The new policy introduces market instability that lowers growth trajectories while it demands that business stakeholders make strategic adjustments for the altered trade conditions.
Key Players Landscape and Outlook
The leading participants within the oral protein and peptides sector apply various tactics to enhance their market standing and maintain their long-term sustainability. Companies are investing in research and development alongside strategic partnerships and market expansion efforts to fuel their innovative activities in this sector. Companies protect their competitive position by obtaining exclusive rights through patent registration that enables them to maintain market control. The companies choose to work with local manufacturers in emerging markets to achieve two important objectives, which include lowering costs and expanding treatment availability to more patients.
For instance, in February 2025, Oramed Pharmaceuticals Inc. announced a joint venture with Hefei Tianhui Biotech Co. Ltd. to spin off its Protein Oral Delivery technology, which aims to redefine diabetes care and transform the future of oral biologics and chronic disease management.
For instance, in December 2024, Merck & Co., Inc. and Hansoh Pharma jointly announced that they are entering into a global licensing agreement for HS-10535, an investigational oral GLP-1 receptor agonist.
For instance, in May 2025, Novo Nordisk A/S is preparing to launch its Wegovy, a blockbuster weight loss medication, in the upcoming years 2026 for the treatment of obesity.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.